{"filings":[{"id":1525996,"accession_number":"0001193125-26-298526","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2026-07-08T20:05:33+00:00","items":["1.02"],"status":"ready","headline":"GSK terminates collaboration with Alector after Phase 3/2 failures; loan repaid","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["GSK provided notice terminating the collaboration agreement for latozinemab and nivisnebart, effective Jan 2, 2027.","Phase 3 INFRONT-3 trial of latozinemab in FTD-GRN missed co-primary endpoint (Oct 2025); Phase 2 PROGRESS-AD of nivisnebart discontinued (Apr 2026).","Alector repaid $10.4M principal plus interest and fees to Hercules Capital, terminating the loan agreement on July 8, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1110999,"accession_number":"0001193125-26-274130","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2026-06-17T20:05:17+00:00","items":["5.07"],"status":"ready","headline":"Alector annual meeting elects three directors, ratifies auditor, passes say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class II directors Elizabeth Garofalo, Errol De Souza, Kristine Yaffe elected with broker non-votes of 36.7M each.","Ernst & Young LLP ratified as auditor for FY2026 with 97.7M votes for, 52K against.","Say-on-pay advisory vote passed with 58.7M for, 2.5M against, 11K abstentions, 36.7M broker non-votes.","Kristine Yaffe received 15.4M votes withheld, notably higher than other director nominees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94437,"accession_number":"0001193125-26-212426","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Alector enters $125M ATM equity facility with TD Cowen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["May sell up to $125M of common stock from time to time through TD Cowen in at-the-market offerings.","TD Cowen will receive up to 3.0% of gross proceeds per share sold; no minimum sales obligation.","Proceeds intended for general corporate purposes, including R&D, manufacturing, and working capital.","Offered under effective shelf registration statement S-3 (File 333-294241) declared effective April 30, 2026.","Company may terminate agreement with 10 days' notice; contains standard representations and indemnities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94436,"accession_number":"0001193125-26-211918","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alector Q1 net loss $22.9M ($0.21/sh); discontinues Phase 2 nivisnebart trial after futility","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $22.9M ($0.21/sh) vs $40.5M ($0.41) in Q1 2025; revenue $1.0M down from $3.7M.","Cash, cash equivalents, and investments $206.5M; runway expected through at least 2027.","Discontinued Phase 2 PROGRESS-AD trial of nivisnebart (AL101) in early AD after futility analysis.","ABC platform progress: AL037/AL137 (anti-Aβ) targeting IND in Q1 2027; AL050 (GCase ERT for PD) preclinical; AL164 (Tau siRNA) in IND-enabling studies.","R&D expenses decreased to $17.9M from $33.6M; G&A $8.1M from $14.7M due to workforce reductions."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":1046000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106819,"accession_number":"0001193125-26-071557","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alector Q4 net loss $37.3M ($0.34/share); revenue down 89% YoY; cash $256M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net loss $37.3M vs $2.1M in Q4 2024; full-year net loss $142.9M ($1.39/share).","Collaboration revenue fell to $6.2M in Q4 from $54.2M a year earlier; full-year revenue $21M.","Cash, equivalents and investments $256M; company expects runway at least through 2027.","Independent interim futility analysis for PROGRESS-AD Phase 2 trial of nivisnebart expected H1 2026.","ABC-led pipeline advancing: AL137 IND filing planned Q4 2026/Q1 2027; AL050 IND target 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":21045000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123125,"accession_number":"0001193125-25-317554","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Alector appoints Neil Berkley as CFO; he continues as CBO, effective Dec 10, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Neil Berkley named permanent CFO; had served as Interim CFO since June 2025.","Berkley remains Chief Business Officer; no change to existing compensation.","Berkley joined Alector in March 2024 as CBO; over 20 years biotech experience.","Press release issued Dec 12, 2025 confirming the appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123124,"accession_number":"0001193125-25-269537","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alector Q3 net loss $34.7M; cash $291.1M; selects lead candidates AL137, AL050; RIF 47%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $34.7M ($0.34/sh) vs $42.2M ($0.43) in Q3 2024; revenue $3.3M, down from $15.3M.","Cash $291.1M, with $20M ATM proceeds Sep-Oct 2025; runway through 2027.","Lead candidates selected: AL137 (ABC anti-amyloid beta, IND 2026) and AL050 (ABC GCase, IND 2027).","Latozinemab Phase 3 INFRONT-3 failed; open-label extension discontinued.","Implemented ~47% workforce reduction in Oct 2025 to focus on priority programs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":14808000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123123,"accession_number":"0001193125-25-245102","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["2.02","2.05","5.02","7.01","9.01"],"status":"ready","headline":"Alector's Phase 3 latozinemab trial fails; workforce cut 49%, R&D head resigns","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 INFRONT-3 trial of latozinemab in FTD-GRN missed clinical co-primary endpoint; biomarker endpoint met but no treatment effects seen.","Workforce reduction of ~49% (about 75 employees); restructuring charges ~$7.7M; completion expected by H1 2026.","President and Head of R&D Sara Kenkare-Mitra resigns effective Dec 22, 2025; separation includes 9 months salary and 50% bonus.","Preliminary cash, equivalents, and short-term investments ~$291.1M as of Sep 30, 2025; runway expected through 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139807,"accession_number":"0000950170-25-105023","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alector Q2 net loss $30.5M; cash $307.3M; Phase 3 latozinemab data mid-Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $30.5M ($0.30/sh) vs $38.7M ($0.40/sh) in Q2 2024; revenue $7.9M down from $15.1M.","Cash, cash equivalents, and investments $307.3M, providing runway into H2 2027.","On track to report topline data from INFRONT-3 Phase 3 trial of latozinemab in FTD-GRN by mid-Q4 2025.","Guidance updated: collaboration revenue $13-18M, R&D expenses $130-140M, G&A $55-65M for FY2025.","Neil Berkley appointed interim CFO; USPTO issued patent for latozinemab treatment method."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":11548000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157395,"accession_number":"0001193125-25-140731","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Alector CFO Marc Grasso resigns; Neil Berkley named interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Marc Grasso resigns effective June 20; Neil Berkley, CBO, becomes interim CFO while continuing as CBO.","Grace Wong-Sarad appointed VP Accounting, serving as principal accounting officer.","Annual meeting elected directors Rosenthal and Hammond, ratified Ernst & Young, approved say-on-pay.","Cash runway into H2 2027; latozinemab Phase 3 top-line data expected Q4 2025.","Berkley base salary $455k, retention bonus $91k; Wong-Sarad base $343,636 (rising to $363,636), retention $54,545."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157394,"accession_number":"0000950170-25-066945","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alector Q1 net loss $40.5M ($0.41/sh); INFRONT-3 data on track for Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $40.5M ($0.41/sh) vs $36.1M ($0.38/sh) in Q1 2024; collaboration revenue $3.7M (down from $15.9M).","Cash, cash equivalents, and investments total $354.6M as of March 31, 2025; runway extended into second half of 2027.","Topline INFRONT-3 Phase 3 data for latozinemab in FTD-GRN expected in Q4 2025; enrollment complete in PROGRESS-AD Phase 2 for AL101.","Giacomo Salvadore appointed Chief Medical Officer; 2025 guidance reiterated: R&D $175-185M, G&A $55-65M, collab rev $5-15M.","Advancing preclinical Alector Brain Carrier programs including anti-amyloid beta antibody and GCase enzyme replacement therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":3700000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175759,"accession_number":"0000950170-25-046756","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Alector CMO Gary Romano resigns effective April 25, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Gary Romano notified resignation from CMO role on March 25, 2025.","Resignation effective April 25, 2025; he leaves to pursue other opportunities.","Romano served as CMO since May 2022; no successor announced yet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175758,"accession_number":"0001193125-25-050448","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Alector cuts workforce by ~13% (25 employees); expects $2.4M restructuring charges","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduction in force impacting ~25 employees, or ~13% of workforce, to align resources with strategic priorities.","One-time restructuring charges of ~$2.4M primarily for severance and benefits.","Cash payments expected and reduction to be completed during Q3 2025.","Company reiterates existing cash will fund operations and capex through 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175757,"accession_number":"0000950170-25-027734","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alector Q4 net loss narrows to $2.1M; latozinemab Phase 3 data expected Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net loss $2.1M ($0.02 loss per share) vs $41.4M loss ($0.49 loss) in Q4 2023, revenue $54.2M vs $15.2M.","Cash, cash equivalents and investments $413.4M, expected to fund operations through 2026.","Topline data from pivotal INFRONT-3 Phase 3 trial of latozinemab in FTD-GRN anticipated by Q4 2025.","Enrollment in PROGRESS-AD Phase 2 trial of AL101/GSK4527226 in early Alzheimer's expected to complete by mid-2025.","2025 guidance: collaboration revenue $5-15M, R&D expense $175-185M, G&A $55-65M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":100600000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175756,"accession_number":"0000950170-25-003811","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"AbbVie terminates TREM2 program and collaboration with Alector after Phase 2 miss","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["INVOKE-2 Phase 2 trial of AL002 in early Alzheimer's disease did not meet primary endpoint (announced Nov 25, 2024).","AbbVie provided written termination notice on Jan 9, 2025 for TREM2 program and the overall collaboration agreement.","Termination effective 30 days from receipt of Jan 9 termination letter; no other programs remain in the partnership.","The TREM2 program was the only remaining program under the AbbVie Agreement, so termination ends the entire collaboration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192693,"accession_number":"0000950170-24-130564","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"Alector AL002 Phase 2 fails primary endpoint; cuts workforce 17%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AL002 did not slow Alzheimer's progression on CDR-SB; no benefit on secondary endpoints or biomarkers.","Stopping long-term extension of INVOKE-2 study; reducing workforce by ~41 employees (17% of staff).","Restructuring charges estimated at $3.9 million, primarily severance and benefits, to be paid by H1 2025.","Cash and investments of $457.2M as of Sep 30, 2024 expected to fund operations through 2026.","Topline data for latozinemab Phase 3 in FTD-GRN expected late 2025/early 2026; AL101/GSK4527226 Phase 2 enrollment over one-third."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192692,"accession_number":"0000950170-24-127056","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Alector secures up to $50M credit facility from Hercules Capital; draws $10M initially","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial $10M drawn at closing; $15M available upon request through June 2026; $25M at lender's discretion.","Interest rate at prime plus 1.05% or 8.05% (greater); maturity December 1, 2028.","Cash and investments $457.2M as of Sept 30, 2024; company believes existing cash funds operations through 2026.","CFO cites transformational data from AL002 Phase 2 and latozinemab Phase 3 trials within current runway.","Facility is secured by substantially all assets, with exceptions for certain existing agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192691,"accession_number":"0000950170-24-122296","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alector reports Q3 net loss $42.2M ($0.43/share); cash $457.2M funds through 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, investments $457.2M as of Sep 30, 2024, sufficient to fund operations through 2026.","Q3 2024 net loss $42.2M ($0.43 per share) vs $44.5M ($0.53) in Q3 2023; collaboration revenue $15.3M, up from $9.1M.","R&D expenses $48.0M driven by AL101 Phase 2 start; G&A $15.8M includes impairment from lab transition.","FY 2024 guidance: collaboration rev $60-70M, R&D $210-220M, G&A $60-70M.","INVOKE-2 (AL002) Phase 2 data due in 2024; INFRONT-3 (latozinemab) top-line late 2025/early 2026; PROGRESS-AD >1/3 enrolled."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":46318000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209139,"accession_number":"0000950170-24-092779","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alector Q2 net loss $38.7M vs $1.4M income YoY; cash $503M, INVOKE-2 data on track for Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $38.7M ($0.40 per share) compared to net income of $1.4M in Q2 2023.","Revenue fell to $15.1M from $56.2M YoY, primarily due to contract modifications on AL101 and AL002 programs.","Cash, cash equivalents and investments total $503.3M, expected to fund operations through 2026.","INVOKE-2 Phase 2 data for AL002 in early Alzheimer's disease anticipated in Q4 2024.","FDA feedback supports potential path to approval for latozinemab in FTD-GRN using biomarkers as confirmatory evidence."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":30976000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227016,"accession_number":"0000950170-24-072512","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Alector shareholders elect all three director nominees, ratify EY, approve say-on-pay at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Louis J. Lavigne, Jr. elected with 72,044,245 votes for, 884,614 withheld.","Richard H. Scheller elected with 68,683,687 for, 4,245,172 withheld.","Mark Altmeyer elected with 72,756,082 for, 172,777 withheld.","Ernst & Young LLP ratified as auditor for FY2024: 85,844,010 for, 191,307 against.","Say-on-pay advisory vote approved: 72,009,466 for, 858,589 against, 60,804 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227015,"accession_number":"0000950170-24-055652","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alector Q1 net loss $36.1M ($0.38/share); cash runway through 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $36.1M ($0.38/share) vs $45.9M ($0.55) in Q1 2023.","Collaboration revenue $15.9M, roughly flat vs $16.5M year ago.","Cash, equivalents & investments $562.1M; expects runway through 2026.","INVOKE-2 Phase 2 TREM2 data for early Alzheimer's expected Q4 2024; INFRONT-3 Phase 3 latozinemab fully enrolled.","Neil Berkley named CBO; Errol De Souza and Mark Altmeyer join Board."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":15900000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245941,"accession_number":"0001193125-24-073821","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Alector announces director resignation and appointment of two new board members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Terry McGuire resigns from Board and all committees effective March 20, 2024; personal reasons, no disagreement.","Errol De Souza, Ph.D. and Mark Altmeyer appointed to Board on March 19, 2024.","De Souza as Class II director (term to 2026 annual meeting); Altmeyer as Class III (term to 2024 annual meeting).","Board size increased to ten then reduced to nine after McGuire's resignation.","Each new director receives initial equity: option for 19,420 shares and RSU for 41,250 shares, vesting over time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245940,"accession_number":"0000950170-24-021133","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alector reports Q4 net loss $41.4M; cash runway extended to 2026 after $75M equity offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $41.4M ($0.49/sh) vs $52.4M ($0.63) YoY; FY net loss $130.4M ($1.56) vs $133.3M ($1.62).","Cash $548.9M at Dec 31; pro forma $620M after Jan 2024 equity offering, providing runway through 2026.","INVOKE-2 Phase 2 enrollment completed (381 pts); data due Q4 2024. Latozinemab granted FDA Breakthrough Therapy for FTD-GRN.","First patient dosed in PROGRESS-AD Phase 2 trial of AL101/GSK4527226 for early AD in Feb 2024.","2024 guidance: collaboration revenue $60-70M, R&D $210-230M, G&A $60-70M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":97100000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245939,"accession_number":"0001193125-24-010647","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2024-01-19T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Alector prices $75M public offering of ~10.9M shares at $6.57 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 10.9M shares at $6.57; gross proceeds ~$75M before discounts and expenses.","Underwriter (Cantor Fitzgerald) has 30-day option to buy up to 1.63M additional shares.","Offering expected to close Jan 19, 2024, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245938,"accession_number":"0001193125-24-008551","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2024-01-16T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Alector reports preliminary cash of ~$549M as of Dec 31, 2023; runway into H2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, cash equivalents, and short-term investments of ~$549 million as of December 31, 2023.","Company expects this cash will fund operating and capital expenditure needs into the second half of 2026.","Estimate is preliminary, unaudited, and subject to change upon completion of year-end financial close.","Independent auditor has not audited or reviewed these preliminary figures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263398,"accession_number":"0001193125-23-272546","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Alector signs $125M ATM equity sales agreement with TD Cowen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $125 million of common stock may be sold from time to time in at-the-market transactions.","TD Cowen will receive up to 3.0% of gross proceeds as compensation.","Proceeds for general corporate purposes, including R&D, working capital, and possible acquisitions.","Sales under existing effective shelf registration statement (Form S-3) filed May 1, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263397,"accession_number":"0000950170-23-060244","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alector Q3 net loss $44.5M ($0.53/share); cash runway through 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Collaboration revenue $9.1M, down from $14.9M YoY; net loss $44.5M vs $46.1M in Q3 2022.","Cash, equivalents & investments $588.9M; management expects sufficient runway through 2025.","Completed enrollment in pivotal INFRONT-3 Phase 3 trial of latozinemab for FTD-GRN with 103 symptomatic participants.","Completed enrollment in INVOKE-2 Phase 2 trial of AL002 for early Alzheimer's; data readout expected Q4 2024.","Reaffirmed FY 2023 guidance: collaboration revenue $90-100M, R&D $210-220M, G&A $60-65M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":81872000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280613,"accession_number":"0000950170-23-037982","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alector reports Q2 net income $1.4M, cash $630M; updates clinical trial timelines","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2023 revenue $56.2M (down 30% YoY); net income $0.02 EPS vs $0.12 EPS in Q2 2022.","Cash, equivalents & investments $630M, expected to fund operations through 2025.","Guidance updated: 2023 collaboration revenue $90-100M (up), R&D $210-220M (down), G&A $60-65M.","Invoke-2 Phase 2 (AL002) enrollment completion Q3 2023; data readout Q4 2024.","INFRONT-3 pivotal trial enrollment completion expected Q4 2023; primary analysis on ~90-100 symptomatic FTD-GRN participants."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":72763000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299225,"accession_number":"0001193125-23-167891","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Alector amends bylaws, elects directors, ratifies auditor at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Bylaws amended effective June 15, 2023, to update stockholder nomination procedures and comply with Delaware law and universal proxy rules.","At June 14 annual meeting, all three Class II director nominees elected: Garofalo (60.7M for), McGuire (54.3M for), Yaffe (54.1M for), each with ~11M broker non-votes.","Ernst & Young ratified as independent auditor for FY2023 (72.5M for, 64.6K against, 64.7K abstain).","Say-on-pay proposal approved on non-binding advisory basis (58.1M for, 3.4M against, 143K abstain)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299224,"accession_number":"0000950170-23-017859","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alector Q1 net loss $45.9M, cash $669.3M; on track for latozinemab INFRONT-3 regulatory engagement in mid-2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $16.5M (down $8M YoY); net loss $45.9M ($0.55/share) vs $44.6M ($0.54/share) in Q1 2022.","Cash, equivalents and investments $669.3M; management expects runway through 2025.","On track to discuss INFRONT-3 (latozinemab in FTD-GRN) with regulators mid-2023; data readout early 2025.","Received $17.8M milestone from AbbVie for AL002 LTE enrollment; INVOKE-2 top-line data expected Q4 2024.","2023 guidance: collaboration revenue $15-25M, R&D expense $225-245M, G&A $60-70M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":16549000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299223,"accession_number":"0001193125-23-122184","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2023-04-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director and Chairperson Tillman Gerngross to resign from Alector's board in June 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gerngross resigns as Board Chairperson effective June 13, 2023, and as director effective June 15, 2023.","Resignation is for personal reasons; no disagreement with Company's operations, policies, or practices.","No replacement named; Board will need to fill Chairperson and director vacancies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319396,"accession_number":"0000950170-23-010593","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2023-03-29T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Alector cuts workforce by 11% (30 employees) to focus on late-stage immuno-neurology programs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~11% (30 employees) effective March 29, 2023.","One-time restructuring charges of ~$2.2M for severance and benefits.","Company reaffirms cash runway through 2025 beyond key clinical milestones.","Plan expected to be completed in first half of 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319395,"accession_number":"0000950170-23-007443","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Alector reports ~1% cash at Silicon Valley Bank; no material impact expected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["As of March 10, 2023, ~1% of total cash, cash equivalents, and marketable securities held at SVB.","Majority of operating cash held at JPMorgan Chase & Co.; asset management portfolio custodied at U.S. Bancorp.","Company does not use SVB for payroll; no material impact on operations or payroll obligations expected.","FDIC appointed receiver for SVB; Treasury, Fed, FDIC approved full depositor protection on March 12."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319394,"accession_number":"0000950170-23-005091","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alector reports Q4 2022 net loss of $52.4M; cash runway through 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2022: $52.4M ($0.63/share) vs $55.6M ($0.68) in Q4 2021; full-year net loss $133.3M ($1.62) vs $36.3M ($0.45).","Cash, cash equivalents, investments $712.9M as of Dec 31, 2022; management expects runway through 2025.","2023 guidance: collaboration revenue $15-25M, R&D expenses $225-245M, G&A expenses $60-70M.","INVOKE-2 Phase 2 enrollment completion expected Q3 2023, data by Q4 2024; $17.8M milestone from AbbVie triggered.","INFRONT-3 pivotal trial for latozinemab: regulatory engagement mid-2023, data readout early 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":133600000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337591,"accession_number":"0000950170-22-023214","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alector Q3 2022 net loss $46.1M, cash $758.3M, pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $46.1M ($0.56 loss per share); prior-year net income $126.6M ($1.56 EPS).","Collaboration revenue $14.9M, down from $182.4M YoY due to $173.4M GSK license in 2021.","Cash, cash equivalents and investments $758.3M; runway through 2024.","Enrolling Phase 3 INFRONT-3 (latozinemab for FTD-GRN) and Phase 2 INVOKE-2 (AL002 for early AD).","Initiated Phase 1 for AL044 (MS4A target for Alzheimer’s); IND for AL009 (immuno-oncology) expected Q4 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":119177000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337590,"accession_number":"0001193125-22-258328","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2022-10-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Alector Chief Development Officer Robert King resigns effective Oct 28, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert King, Ph.D., Chief Development Officer, resigned effective October 28, 2022.","He stepped down to pursue another professional opportunity outside the company.","No successor has been announced at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354958,"accession_number":"0001193125-22-250294","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2022-09-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Alector increases inducement equity plan shares to 3.3M for new employee hiring","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved amendment raising shares available under 2022 Inducement Plan from 1,630,000 to 3,300,000.","Plan is material inducement for new employees entering employment, per Nasdaq Listing Rule 5635(c)(4).","Amendment adopted without stockholder approval as permitted under Nasdaq rules for inducement awards.","Awards under plan include nonstatutory stock options, RSUs, restricted stock, and performance shares.","Plan and forms of award agreements filed as Exhibit 10.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354957,"accession_number":"0000950170-22-014801","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alector Q2 net income $9.9M, cash $808.9M; AL044 IND submitted","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $9.9M ($0.12/share) vs net loss $55.1M ($0.69) in Q2 2021; collaboration revenue rose to $79.9M from $6.6M.","Cash, equivalents and investments $808.9M; estimated runway into second half of 2024.","IND submitted for AL044 targeting MS4A, a genetic risk locus for Alzheimer's; first study in healthy volunteers planned.","Expanding sites for INFRONT-3 Phase 3 of latozinemab in FTD-GRN; Phase 1 data for AL101 expected later 2022.","Peter Heutink appointed CSO; John Maraganore as strategic advisor; AbbVie terminates CD33 collaboration (AL003)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":104325000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354956,"accession_number":"0001193125-22-189463","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2022-07-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"AbbVie terminates Alector's AL003/CD33 Alzheimer's collaboration","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AbbVie provided written notice on June 30, 2022 terminating the CD33 (AL003) program.","Alector and AbbVie continue to advance the AL002 (TREM2) program under the existing agreement.","No financial or milestone termination payments disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373014,"accession_number":"0001193125-22-177617","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2022-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Alector annual meeting results: all director nominees elected, auditor ratified, say-on-pay approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class I directors Rosenthal, Hammond, Wehner elected with ~94% votes for each against votes withheld.","Ratification of Ernst & Young as auditor for FY 2022 passed with 74,118,873 for, 88,025 against.","Say-on-pay advisory vote approved: 62,031,465 for, 1,137,494 against, 11,025,912 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373013,"accession_number":"0000950170-22-007824","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alector Q1 rev $24.5M, net loss $44.6M; latozinemab shows 54% disease progression delay in FTD-C9orf72","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Collaboration revenue $24.5M (vs $4.1M YoY) from GSK agreement; net loss $44.6M ($0.54/share) improved from $52.2M loss.","Cash, cash equivalents, and marketable securities $868.6M; sufficient to fund operations into mid-2024.","INFRONT-2 Phase 2: latozinemab in FTD-C9orf72 showed ~54% annual delay in disease progression vs matched control.","AL101 Phase 1 enrollment completed; data expected H2 2022. AL044 Phase 1 to initiate H2 2022.","Gary Romano, M.D., Ph.D., joins as CMO on May 23, 2022; Marc Grasso, M.D., joined as CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":24474000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391802,"accession_number":"0000950170-22-004925","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2022-03-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Alector appoints Gary Romano, M.D., Ph.D., as CMO effective May 23, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Gary Romano, M.D., Ph.D., as Chief Medical Officer, effective May 23, 2022.","Annual base salary of $475,000; eligible for performance bonus of 40%; equity awards: $3.9M stock option (4-yr vest) and $975K RSU (3-yr vest).","He brings over 25 years of neurodegenerative disease experience, previously CMO at Passage Bio and roles at Janssen and Merck.","Interim CMO Sam Jackson, M.D., M.B.A., is leaving Alector to pursue a new opportunity; will continue as a consultant.","He will report to President and Head of R&D Sara Kenkare-Mitra."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391801,"accession_number":"0000950170-22-001969","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2022-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alector Q4 2021 net loss $55.6M; cash $735M plus $200M from GSK; pipeline advancing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2021 $55.6M ($0.68/share) vs $52.2M ($0.66) in Q4 2020; full-year net loss $36.3M ($0.45) vs $190.2M ($2.45).","Collaboration revenue Q4 $14.0M (up from $4.9M); full-year $207.1M (up from $21.1M) driven by GSK deal.","Cash $735.3M at Dec 31, 2021; plus $200M from GSK in Jan 2022. Cash runway expected into mid-2024.","AL002 Phase 2 ARIA observed; protocol amended to exclude APOE e4/e4 homozygotes.","Appointed Sara Kenkare-Mitra (President/Head R&D) and Marc Grasso (CFO)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":207085000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391800,"accession_number":"0000950170-22-000835","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2022-02-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Alector appoints Marc Grasso, M.D. as CFO; base salary $480K, stock option 450K shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Marc Grasso appointed CFO effective Feb 7, 2022; succeeds interim CFO Linda Rubinstein.","Annual base salary $480,000; eligible for performance bonus up to 40% of salary.","Received sign-on bonus of $103,000 and stock option for 450,000 shares vesting over 4 years.","Grasso previously CFO and CBO at Kura Oncology; brings investment banking background.","Rubinstein continues as Principal Financial Officer and Accounting Officer until Feb 25, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391799,"accession_number":"0001193125-22-000619","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2022-01-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"President and COO Shehnaaz Suliman departs Alector; receives $375K severance, stock option acceleration","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Last day of employment December 31, 2021; separation agreement includes $375,000 severance payment and $337,500 bonus.","Company will pay COBRA premiums for 9 months through September 30, 2022.","Incentive stock options that would vest in 9 months after separation become fully vested; 100,000 PSUs remain unvested and canceled.","Dr. Suliman had 32,981 ISO, 706,232 NQSO, and 100,000 PSUs originally; as of separation 17,412 ISO and 451,377 NQSO vested.","She has 3 months post-separation to exercise vested options; unvested options and PSUs forfeited."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391798,"accession_number":"0001193125-22-000212","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2022-01-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Alector adopts 2022 Inducement Equity Plan, reserves 1.63M shares for new hires","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board adopted 2022 Inducement Plan effective Jan 1, 2022, reserving 1,630,000 shares of common stock.","Plan allows grants of options, RSUs, restricted stock, SARs, performance shares/units to new employees.","Awards intended as inducements under Nasdaq Listing Rules; no stockholder approval required.","Plan terms substantially similar to 2019 Equity Incentive Plan.","Inducement Plan only for individuals not previously employees, or after bona-fide non-employment period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410055,"accession_number":"0000950170-21-005217","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2021-12-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Alector appoints Sara Kenkare-Mitra as President and Head of R&D","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Kenkare-Mitra joins from Genentech, most recently SVP of Development Sciences.","Annual base salary of $570,000; eligible for 100% bonus and $500,000 sign-on bonus.","Equity grants: 300,000 stock options (4-yr vest), 59,000 RSUs (3-yr vest), 59,000 PSUs (1-yr performance-based vest).","She will report to CEO Arnon Rosenthal and lead all immuno-neurology and oncology R&D efforts.","Effective December 15, 2021; includes standard change-in-control and severance agreement (Tier 2)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410054,"accession_number":"0000950170-21-003064","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alector reports Q3 net income $126.6M ($1.56/share) vs loss year-ago; GSK collaboration boosts revenue","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Collaboration revenue $182.4M (vs $5.9M YoY) driven by $500M upfront from GSK deal.","Cash, cash equivalents & marketable securities $777.9M as of Sep 30, 2021.","Initiated Phase 2 trial of AL001 in ALS patients with C9orf72 mutation; primary endpoint safety & PK/PD.","Sam Jackson, M.D., appointed interim CMO; Linda Rubinstein interim CFO; Elizabeth Garofalo, M.D. joins board.","Net income $126.6M ($1.56 diluted EPS) compared to net loss $52.7M ($0.67 loss) in Q3 2020."],"consensus_eps_estimate":null,"consensus_eps_actual":0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":193091000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":428918,"accession_number":"0001193125-21-284964","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2021-09-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Alector appoints Elizabeth Garofalo, M.D. to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Garofalo appointed as Class II director with term expiring at 2023 annual meeting; effective Sept. 23, 2021.","Over 25 years of neurology drug development experience; formerly SVP and Global Head of Clinical Development at Novartis.","Received initial option grant of 33,235 shares (four-year vest) and annual cash retainer of $40,000.","Currently serves on boards of Acadia Pharmaceuticals, Exicure Inc., and Xenon Pharmaceuticals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":428917,"accession_number":"0000950170-21-001712","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2021-09-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Alector appoints Linda Rubinstein as interim CFO; Calvin Yu steps down as principal accounting officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Linda Rubinstein, partner at FLG Partners, appointed interim CFO, Principal Financial Officer and Principal Accounting Officer effective Sept 8, 2021.","Alector will pay FLG Partners $600 per hour for Ms. Rubinstein's services under a consulting agreement.","Calvin Yu no longer serves as Principal Financial Officer or Principal Accounting Officer; he remains VP of Finance.","Ms. Rubinstein has over 30 years of life sciences finance experience, previously serving as consulting CFO for firms including Apexigen, Five Prime, and Kezar Life Sciences."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":245920787.93212667,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-09-08T23:59:59+00:00|428917"}